Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract

Annals of Oncology, 04/04/2012

Everolimus showed clinical activity in advanced transitional carcinoma cell (TCC). The profile of the plasma angiogenesis–related proteins suggested a role of the everolimus antiangiogenic properties in disease control. PTEN loss might be associated with everolimus resistance.

Print Article Summary Cat 2 CME Report